Armata Pharmaceuticals, Inc. (ARMP)
| Market Cap | 81.33M |
| Revenue (ttm) | 5.45M |
| Net Income (ttm) | -32.65M |
| Shares Out | 36.04M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,313 |
| Open | 2.33 |
| Previous Close | 2.25 |
| Day's Range | 2.05 - 2.37 |
| 52-Week Range | 1.85 - 6.46 |
| Beta | -0.04 |
| Analysts | Buy |
| Price Target | 8.16 (+298.0%) |
| Earnings Date | Nov 9, 2022 |
About ARMP
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to tar... [Read more]
Financial Performance
In 2021, ARMP's revenue was $4.47 million, an increase of 443.62% compared to the previous year's $823,000. Losses were -$23.16 million, 4.39% more than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ARMP stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 298.05% from the latest price.
News
After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana...
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
MARINA DEL REY, Calif. , Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...
Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing
Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisio...
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update
MARINA DEL REY, Calif. , Nov. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0% and 98.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update
MARINA DEL REY, Calif. , Aug. 11, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections
Second indication for AP-SA02 which targets Staphylococcus aureus including MRSA Potential to significantly improve PJI patient outcomes Expands Armata's pursuit of phage therapy as a solution for diffi...
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacterem...
Study conducted in partnership with the US Department of Defense MARINA DEL REY, Calif. , May 23, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a b...
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Tops Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of -50% and 30.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update
MARINA DEL REY, Calif , May 12, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage th...
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva
MARINA DEL REY, Calif. , March 31, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...
Wall Street Analysts See a 52% Upside in Armata Pharmaceuticals, Inc. (ARMP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 52.5% in Armata Pharmaceuticals, Inc. (ARMP). While the effectiveness of this highly sought-after metric is quest...
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
MARINA DEL REY, Calif., March 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...
HATCHspaces®, NexCore Group, and Nuveen Real Estate to Convert 56,300 SF Industrial Building to Biomanufacturing in W...
LOS ANGELES & DENVER--(BUSINESS WIRE)-- #Bioscience--HATCHspaces®, NexCore Group, and Nuveen Real Estate have acquired a 56,300 SF Industrial Building to convert to Biomanufacturing in West Los Angeles.
Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial...
MARINA DEL REY, Calif., Feb. 22, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...
Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences
MARINA DEL REY, Calif., Feb. 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...
Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Develop...
MARINA DEL REY, Calif., Feb. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage th...
Recent Price Trend in Armata Pharmaceuticals, Inc. (ARMP) is Your Friend, Here's Why
Armata Pharmaceuticals, Inc. (ARMP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that pa...
Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs
MARINA DEL REY, Calif., Jan. 5, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific ba...
Wall Street Analysts Believe Armata Pharmaceuticals, Inc. (ARMP) Could Rally 47%: Here's is How to Trade
The mean of analysts' price targets for Armata Pharmaceuticals, Inc. (ARMP) points to a 46.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree...
Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therape...
MARINA DEL REY, Calif., Nov. 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific b...
What Makes Armata Pharmaceuticals, Inc. (ARMP) a New Buy Stock
Armata Pharmaceuticals, Inc. (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 15.38% and 23.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...
Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update
MARINA DEL REY, Calif., Nov. 10, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...